MK-677 vs Ipamorelin and CJC-1295: Oral vs Injectable GH Secretagogues in Research

MK-677 dominates the search conversation about growth-hormone secretagogues, largely because it is oral. But "oral GH pill" versus "injectable peptide" is only one of the differences, and it is not even the most important one. This article compares MK-677, Ipamorelin and CJC-1295 on the axes that actually matter in the research literature: receptor pathway, route, kinetics, selectivity and depth of human evidence. MK-677 itself is used here purely as a comparison and search-bridge term; it is not stocked or orderable, and every practical pointer funnels to the two stocked research peptides and their blend. Everything is written for laboratory research context only, with no dosing or usage guidance.

Growth & Performancegrowth

Growth hormone secretagogues and gonadotropins

Two Receptors, One Goal

The single most useful way to organise these three compounds is by the receptor they act on. Two distinct pituitary pathways both raise GH:

• The ghrelin receptor (GHS-R1a), activated by MK-677 (an oral non-peptide agonist) and by Ipamorelin (an injectable selective peptide GHRP).
• The GHRH receptor, activated by CJC-1295 (a GHRH analogue).

Because the two pathways are separate and complementary, agents that hit them provide a theoretical complementary-pathway rationale for pairing a GHRP with a GHRH analogue in research designs. So "MK-677 versus Ipamorelin" is a same-receptor, different-route, different-duration comparison, while "versus CJC-1295" is a different-pathway comparison.

MK-677 (Ibutamoren): The Oral Ghrelin Agonist

MK-677's defining property is the sustained duration of its effect: once-daily oral dosing produces near-continuous IGF-1 elevation across roughly 24 hours, while the underlying GH release itself stays pulsatile (the study reported enhanced pulsatile GH secretion, PMID 8954023). That sustained pattern is also the setting in which its GH-associated and ghrelin-mediated effects were reported: appetite stimulation, fluid retention and the reduced insulin sensitivity noted above. A short-term study showed it can be nitrogen-sparing during energy restriction (nitrogen balance +0.31 g/day on MK-677 versus -1.48 g/day on placebo, PMID 9467534), a mechanistic anabolic signal downstream of GH and IGF-1, not a treatment claim. And a clean cautionary example: in Alzheimer's disease, MK-677 confirmed target engagement (IGF-1 rose about 73 percent at 12 months) but produced no clinical benefit (PMID 19015485), a reminder that raising IGF-1 is not the same as a disease effect.

Ipamorelin: The Selective GHRP

Ipamorelin is a pentapeptide that hits the same ghrelin receptor (GHS-R1a) as MK-677, but it behaves very differently. It triggers a short, discrete GH pulse, and its defining feature is selectivity. In its characterisation study, which is largely preclinical, it released GH potently while, unlike the earlier GHRPs GHRP-6 and GHRP-2, not raising ACTH or cortisol above the level seen with GHRH alone, and it was described as the first selective growth hormone secretagogue (PMID 9849822). Being a peptide, it is not orally bioavailable, so it is used by injection in research. Where MK-677 gives a flat, prolonged curve, Ipamorelin gives a clean spike.

Ipamorelingrowth

Highly selective growth hormone releaser that triggers natural GH pulses without raising cortisol or prolactin. Clean GH stimulation with minimal side effects - the most targeted growth hormone peptide available.

CJC-1295: The DAC Study Data and the No-DAC Stocked Form

CJC-1295 acts on a different receptor, the GHRH receptor. Its DAC (drug-affinity-complex) version binds albumin to extend its half-life dramatically. In healthy adults, a single dose of CJC-1295 DAC produced dose-dependent 2- to 10-fold increases in mean GH for six or more days and 1.5- to 3-fold increases in IGF-1 for 9 to 11 days, with an estimated half-life of 5.8 to 8.1 days and IGF-1 staying above baseline up to about 28 days after repeated dosing (PMID 16352683). Crucially, despite continuous GHRH-receptor stimulation, GH kept its pulsatile pattern: pulse frequency and magnitude were unchanged while basal GH rose sharply (about 7.5-fold), mean GH rose about 46 percent and IGF-1 about 45 percent (PMID 17018654).

CJC-1295 (No DAC)growth

CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH(1-29) analog for GH/IGF-1 research. Research-grade lyophilized powder, specified purity >=99% (HPLC). Laboratory use only.

Oral vs Injectable, and Pulsatile vs Sustained

Two contrasts capture most of the practical difference between these compounds.

Route. MK-677 is orally active because it is a small non-peptide molecule; Ipamorelin and CJC-1295 are peptides and are used by injection in research. That is the headline convenience difference, and the reason MK-677 gets so much search attention.

Curve shape. This is the more meaningful difference. Ipamorelin produces a short sharp pulse that mimics a ghrelin surge. CJC-1295 DAC raises the baseline while keeping pulses intact over days. MK-677 gives a flat, prolonged 24-hour elevation. That continuum, from a discrete pulse to elevated-with-pulses to flat-sustained, is the clearest way to see how the three differ. It was under MK-677's flat, sustained ghrelin-receptor activation that appetite stimulation, fluid retention and reduced insulin sensitivity were reported in its trials (PMID 18981485); Ipamorelin's brief pulse and the injectable GHRH analogues were studied under different exposure patterns, and these studies do not establish a single exposure-response rule linking the three.

What the Human Data Do and Do Not Show

Why Researchers Pair a GHRP With a GHRH Analogue

Because Ipamorelin (ghrelin pathway) and CJC-1295 (GHRH pathway) engage two complementary pituitary pathways, combining them is a theoretical complementary-pathway rationale, and the CJC-1295 and Ipamorelin blend exists for that research pairing. This is a mechanistic rationale, not an efficacy, synergy or dosing claim, and the supplied studies do not test the combination.

CJC-1295 (No-DAC)/Ipamorelingrowth

2-in-1 growth hormone blend: CJC-1295 no-DAC (Modified GRF 1-29, 5 mg) + Ipamorelin (5 mg) combined in one vial. The CJC-1295 component is the short-acting no-DAC variant (about 30 minute half-life), not the long-acting DAC form. Stimulates natural GH release through two different pathways for amplified, more physiological growth hormone pulses.

Stocked Research Peptides and Handling

Of the three compounds compared here, Ipamorelin and CJC-1295 (and the combined blend) are the ones stocked as research peptides; MK-677 is discussed for comparison only and is not offered. The stocked CJC-1295 and blend are the short-acting no-DAC (modified GRF 1-29) form, not the long-acting DAC form whose multi-day data appear above. The stocked compounds are supplied for laboratory research and are not intended for human consumption. This article contains no dosing, reconstitution-for-injection or cycling guidance. Check the supplier-provided, batch-specific third-party Certificate of Analysis for the tested batch, and see the growth hormone peptides overview and the IGF-1 biomarker explainer for the wider picture.

Frequently Asked Questions

This article is for research and educational purposes only. MK-677 is discussed for scientific comparison and is not offered for sale. Nothing here is medical advice, a health claim, dosing guidance or a recommendation for use, and study findings are not outcomes a reader can obtain. All stocked compounds mentioned are sold exclusively for laboratory research.